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The objective of this study was to examine the relationship between adipokines and adiposity in individuals with rheumatoid and
osteoarthritis in the Atlantic PATH cohort. Using a nested case-control analysis, participants in the Atlantic PATH cohort with
rheumatoid or osteoarthritis were matched for measures of adiposity with participants without a history of arthritis. Both
measured and self-reported data were used to examine disease status, adiposity, and lifestyle factors. Immunoassays were used to
measure plasma markers. BMI was positively correlated with percentage body fat, fat mass index (FMI), and a change in BMI from
18 years of age in all 3 groups. There were no statistical diﬀerences between levels of plasma adipokines; adiponectin levels were
6.6, 7.9, and 8.2μg/ml, leptin levels were 10.3, 13.7, and 11.5 ng/ml, and resistin levels were 10.0, 12.1, and 10.8 ng/ml in
participants without arthritis, with rheumatoid arthritis, and with osteoarthritis, respectively. Those with higher levels of
adiponectin were more likely to have osteoarthritis (but not rheumatoid arthritis). No association was found between arthritis
types and leptin or resistin. This study demonstrates diﬀerences in measures of adiposity and adipokines in speciﬁc types of
arthritis and highlights the need for more research targeting speciﬁc adipokines during arthritic disease progression.
1. Introduction
Arthritis is a condition that aﬀects joints and the surrounding
tissues, causing chronic pain, limiting mobility, and con-
tributing to disability. The Atlantic Provinces have some
of the highest rates of arthritis in Canada; the overall
prevalence of arthritis in Canada is approximately 16%,
whereas Newfoundland and Labrador, Nova Scotia, and
New Brunswick each report a prevalence of 25% [1].
Research suggests that there are nonmodiﬁable risk
factors such as age, sex, and genetics that impact the risk of
developing arthritis. For example, data from the Canadian
Community Health Survey in 2014 indicated similar rates
of individuals who report being diagnosed with arthritis at
younger ages, but at 45 years of age, the prevalence of
arthritis is higher in females than in males [1]. Modiﬁable
risk factors including physical activity, diet, and maintaining
a healthy body weight may also prevent disease progression,
reduce pain, and improve movement [2].
Excess body weight is associated with many comorbidi-
ties that decrease lifespan, produce a substantial economic
burden, and increase the risk of multiple chronic diseases.
Similar to the high rates of arthritis, the percent of individ-
uals that are obese in Atlantic Canada (24–30%) is well
above the national average (20%) [3]. Meta-analyses have
demonstrated a dose response in the prevalence of both
rheumatoid and osteoarthritis with increasing body mass
index (BMI) [4–7].
Earlier work suggested that a simple mechanical mecha-
nism was responsible for the relationship between obesity
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and arthritis. But more recently, associations between obesity
and non-weight-bearing joints suggest that the mechanism
might be more complex, involving adipose-tissue-derived
proteins that have immunomodulatory and bone remodel-
ing properties [8]. In obesity, there are substantial changes
in the inﬂammatory mediators (cytokines and adipokines)
secreted from adipose tissue [9], which may regulate phys-
iological actions in tissue and cells of the joints involved in
arthritic disease progression [10, 11]. The adipokine known
as adiponectin is generally considered anti-inﬂammatory,
and circulating levels decrease with obesity. However, in
the case of arthritis, adiponectin may act as a proinﬂam-
matory mediator by promoting the degradation of joint
tissues [11, 12]. Thus, the complex relationship between
these adipokines in arthritis is not yet fully understood
and direct comparisons of adipokine levels in both lean
and obese individuals with speciﬁc types of arthritis (osteoar-
thritis versus rheumatoid) are lacking. While rheumatoid
arthritis has long been viewed as an inﬂammatory condition,
more recently, we have started to understand that inﬂam-
matory mediators also play a crucial role in the initiation
and progression of osteoarthritis [13, 14]. Therefore, the
objective of this study was to investigate the association
between plasma adipokine levels in speciﬁc types of arthri-
tis (rheumatoid and osteoarthritis) among a cohort of
Atlantic Canadians.
2. Methods
2.1. Study Population and Data Collection. Questionnaire
data, physical measures, and biological samples were collected
between 2009 and 2015 from participants aged 35 to 69 years
that were residents of New Brunswick, Newfoundland and
Labrador, Prince Edward Island, and Nova Scotia, Canada.
The questionnaires included data on sociodemographic,
health, environmental, and lifestyle factors. Recruitment and
data collection has been previously described [15]. All indi-
viduals provided written informed consent prior to participa-
tion. The original data and sample collection were approved
by the Research Ethics Boards in each Atlantic Canadian
province and the secondary analysis of biological samples
was approved by the Dalhousie University Research Ethics
Board (#2016-3884).
2.2. Assessment of Arthritis, Obesity, and Lifestyle Risk Factors.
The prevalence of arthritis among Atlantic Canadians was
derived from the self-reported incidence of arthritis in the
Atlantic PATH cohort. Participants were asked to respond
“yes” or “no” if a doctor had ever told them that they had
arthritis. If yes, participants indicated the age at ﬁrst diagnosis
as well as the type of arthritis by checking: rheumatoid
arthritis, osteoarthritis, do not know, or other. In the current
study, there were 30549 participants that provided data on
ever being diagnosed with arthritis, and of those participants,
anthropometric measures such as height and weight were
provided by 24569 participants. As part of the questionnaire,
participants were asked to self-report anthropometric data
including height, weight, and waist and hip circumference
measurements. Additionally, body composition (i.e., fat mass
and fat-free mass) was measured by bioelectrical impedance,
using a Tanita Segmental Body Composition Analyzer
(Tanita BC-418), and standard anthropometric measures
(height, weight, and hip and waist circumference) were
collected by research nurses at assessment centres. Both self-
reported and measured height, weight, and waist and hip
circumference were used for calculating BMI and waist-to-
hip ratios. BMI values were used to quantify the percent
of Atlantic PATH participants who were underweight,
normal weight, overweight, or obese as deﬁned by having
a BMI of <18.5, 18.5–24.9, 25.0–29.9, or >30.0, respectively.
Additional adiposity measures, waist-to-hip ratio, and waist
circumference are also useful to identify individuals at an
increased risk of obesity-related comorbidities and were
used as measures of body fat distribution in this study.
The waist-to-hip ratio was set at >0.85 for women [16]
and abdominal obesity was deﬁned as having a waist cir-
cumference≥ 88 cm for women [15, 16]. The fat mass index
and fat-free mass index were calculated by dividing fat mass
and fat-free mass by height in meters squared, respectively
[17]. Questions related to lifestyle and behavior, including
diet, physical activity, smoking, alcohol consumption, and
education were assessed. Education was categorized as high
school or lower, college level, and university level or higher.
For smoking behavior, participants were asked if they had
smoked at least 100 cigarettes in their life and if they
answered no, they were classiﬁed as never smoked. If yes,
participants further answered the question, at the present
time, do you smoke cigarettes daily, occasionally (at least
one in the past 30 days), or not at all (did not smoke at
all in the past 30 days)? And they were classiﬁed as a
current smoker (daily or in the past 30 days) or former
smoker (has not smoked in the past 30 days). For alcohol
consumption, participants were classiﬁed as an abstainer,
occasional drinker (<3 times/month), regular drinker (1–3
times/week), and habitual drinker (4–7 times/week). For
fruit and vegetable intake, total servings of fruit and vegeta-
bles consumed in a typical day were used.
2.3. Assessment of Physical Activity. Participants were asked
to report their levels of physical activity using open-ended
questions in the International Physical Activity Question-
naire (IPAQ long form). Participants were asked to identify
the frequency and duration of all vigorous, moderate, and
walking PA (i.e., inclusive of occupational, domestic, and
leisure time) within the last seven days. Each question
deﬁned the speciﬁc intensity and domain, as well as provided
examples. Using the IPAQ guidelines for data processing and
analyses, daily and weekly metabolic equivalents of a task
(MET) values were calculated for each domain. Total score
of PA in MET (minutes/week) were calculated by summing
up all MET values across all domains. In accordance with
the criteria of IPAQ scoring protocol, categorical PA score
was deﬁned as inactive, moderately active, and active.
2.4. Biological Samples. In addition to the questionnaire and
physical measures data, a subgroup of 21160 participants
provided biological samples. Blood samples were collected
from participants via arm venipuncture into vacutainer tubes
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by a phlebotomist. For plasma samples, blood was collected
in EDTA-containing tubes, inverted 8 times then stored at
4°C for transport. Samples were shipped on ice to a central
processing facility where they were centrifuged at 1500g for
10 minutes at 4°C. Samples were processed within 24 hours
of collection, then aliquoted into cryotubes and placed
in −80°C freezers for long-term storage. Plasma levels of
adipokines were measured by magnetic bead-based immuno-
assays; adiponectin was measured as a singleplex assay (171-
A7003M, Bio-Rad Laboratories), whereas leptin and resistin
were measured together in a multiplex assay (171-A7001M,
Bio-Rad Laboratories). For measurements of adiponectin,
samples were diluted 1 : 400, and for detection of leptin/resis-
tin, samples were diluted 1 : 4. Data were acquired on the
Bio-Plex MAGPIX and Bio-Plex 200 systems (Bio-Rad).
The intra- and inter-assay coeﬃcients of variation were ≤10
and 15%, respectively. Data were analyzed in duplicate
using the Bio-Plex Manger 6.0 software (Bio-Rad).
Since adipokine levels are inﬂuenced by obesity [9] and
participants in the Atlantic PATH cohort with arthritis had
higher reported measures of adiposity compared to those
without arthritis (data not shown), we conducted a nested
case-control study (n = 240) of participants with rheumatoid,
with osteoarthritis, or without arthritis that were matched for
BMI (Table 1). Females were more likely than males to have
arthritis, and arthritis was also increasingly prevalent with
advancing age (data not shown). Thus, to simplify the
analysis and avoid sex/age-based variations, the nested
case-controlled analysis included only female Atlantic PATH
participants over the age of 50 years who self-identiﬁed as
being diagnosed with a speciﬁc type of arthritis (e.g., rheuma-
toid or osteoarthritis).
2.5. Statistical Analysis. Categorical variables are described as
frequencies and percentages, and continuous variables are
described as means± standard deviation. Data analyses were
performed with SPSS (Version 22 IBM) and statistical signif-
icance was deﬁned as P ≤ 0 05. The Kolmogorov-Smirnov
test was used to test for normal distribution of data. If
normally distributed, groups were compared with ANOVA,
and nonnormally distributed groups were compared with
the Kruskal-Wallis test. Pearson’s correlation coeﬃcients
were calculated to assess correlations between diﬀerent
adiposity measures in participants without arthritis, with
rheumatoid arthritis, or with osteoarthritis. Multinomial
logistic regression models were used to assess adipokine
concentrations as predictors of incidence of arthritis.
3. Results
3.1. Characteristics of Participants. The participants in each
of the arthritis groups were older compared to the group
without arthritis. Lifestyle risk factors such as smoking,
alcohol consumption, education, fruit and vegetable intake,
and physical activity level were similar between all three par-
ticipant groups (Table 1). Participants in the case-controlled
analysis not only were matched for BMI, but also had similar
measures of waist circumference, waist-to-hip ratio, percent
body fat, FMI, BMI at 18 years, and a change in BMI from
18 years of age (Table 1).
Since the correlation between BMI and fat mass varies
with age, sex, and disease condition such as rheumatoid
cachexia [18–20], we examined the correlation between mea-
sures of adiposity in each of the study groups. There was a
signiﬁcant correlation between several of the adiposity mea-
sures in participants without arthritis, with rheumatoid
arthritis, and with osteoarthritis (Table 2). More speciﬁcally,
BMI was positively correlated with percentage body fat, FMI,
and change in BMI from 18 years of age. No signiﬁcant asso-
ciation between BMI, waist circumference, or waist-to-hip
ratio was found in any of the groups (Table 2). FMI was
positively correlated with BMI, percent body fat, and a
change in BMI from 18 years of age (Table 2) in all groups.
Waist circumference was positively correlated with the
waist-to-hip ratio in all groups. Waist-to-hip ratio was
inversely correlated with BMI, percentage body fat, and
FMI in participants with rheumatoid arthritis (Table 2).
3.2. Plasma Adipocytokine Levels. Plasma adiponectin levels
were 7.9, 8.2, and 6.6μg/ml in participants with rheuma-
toid, with osteoarthritis, and without arthritis, respectively
(P = 0 16, n = 240) (Figure 1(a)). Plasma leptin levels were
13.7, 11.5, and 10.3 ng/ml in participants with rheumatoid
arthritis, with osteoarthritis, and without arthritis, respec-
tively (P = 0 34, n = 240) (Figure 1(b)). Plasma resistin levels
were 12.1, 10.8, and 10.0 ng/ml in participants with rheuma-
toid arthritis, with osteoarthritis, and without arthritis,
respectively (P = 0 49, n = 240) (Figure 1(c)).
Logistic regression analysis found no signiﬁcant associa-
tion between adipokines and rheumatoid arthritis (Table 3).
In contrast, plasma adiponectin levels were signiﬁcantly
associated with osteoarthritis (Table 4). This relationship
remained after adjusting for age, education, smoking, alcohol
use, and fruit and vegetable consumption (Table 4). There
was no association between plasma leptin or resistin levels
and osteoarthritis (Table 4).
4. Discussion
Arthritis is among the most commonly reported chronic
conditions in Canada and although associations with BMI
have been reported, the underlying molecular mechanisms
are not well understood. This study demonstrates a signiﬁ-
cant association between several measures of adiposity
(BMI, percent body fat, and FMI) in female participants with
arthritis and shows that of several adipokines assessed, only
adiponectin was associated with a speciﬁc type of arthritis.
Previous studies have reported that only 24% of women
with arthritis have a BMI≥ 30.0 [6], whereas a higher preva-
lence of participants with arthritis (38%) had a BMI in the
obese range in the Atlantic PATH cohort (data not shown).
Although, with the ever increasing obese population [3]
and increased incidence of arthritis in those over the age of
45–55 years [21], the prevalence in the current cohort may
not be all that surprising. Several others have reported a
higher incidence of arthritis in those with increasing BMI
[4, 7, 22, 23]. However, BMI is not the only measure
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Table 1: Characteristics of nested case-control participants with and without arthritis in the Atlantic PATH cohort.
No arthritis Rheumatoid Osteoarthritis
n (%)
Age group
50–59 49 (61.3) 35 (43.8) 36 (45.0)
60–69 31 (38.8) 45 (56.3) 44 (55.0)
Province
Nova Scotia 43 (53.8) 40 (50.0) 38 (47.5)
New Brunswick 22 (27.5) 15 (18.8) 22 (27.5)
Newfoundland and Labrador 6 (7.5) 20 (25.0) 15 (18.8)
Prince Edward Island 9 (11.3) 5 (6.3) 5 (6.3)
Education
High school or less 14 (17.5) 20 (25.3) 13 (16.3)
College level 24 (28.6) 33 (41.8) 27 (33.8)
University level 42 (52.5) 26 (32.9) 40 (50.0)
Smoking status
Never 40 (50.0) 33 (41.3) 38 (47.5)
Former 35 (43.8) 42 (52.5) 35 (43.8)
Current 5 (6.3) 5 (6.3) 7 (8.8)
Alcohol drinking
Abstainer 12 (15.0) 15 (18.8) 12 (15.0)
Occasional drinker 32 (40.0) 36 (45.0) 34 (42.5)
Regular drinking 23 (28.7) 24 (30.0) 18 (22.5)
Habitual drinker 13 (16.3) 5 (6.3) 16 (20.0)
Fruits & vegetables (ﬁve a day) 57 (71.3) 43 (53.8) 46 (57.5)
Diabetes 17 (3.8) 25 (8.8) 26 (7.6)
Hypertension 3 (21.3) 7 (32.1) 6 (32.5)
BMI> 30 40 (33.3) 40 (33.3) 40 (33.3)
Waist-to-hip ratioa 53 (66.3) 54 (67.5) 52 (65.8)
Abdominal obesityb 42 (52.5) 54 (67.5) 54 (68.4)
Physical activity levelc
Inactive 16 (20.0) 22 (27.8) 13 (16.3)
Moderately active 21 (26.3) 20 (25.3) 20 (25.0)
Active 43 (53.8) 37 (46.8) 47 (58.8)
Mean (SD)
Age 57.7 (5.1) 60.3 (5.6)∗ 59.7 (5.1)∗
Duration of arthritis (years) — 15.8 (15.7)$ 10.5 (10.0)
Height, cm 166.0 (10.2) 166.5 (8.7) 165.1 (9.2)
Weight, kg 78.9 (24.2) 78.5 (20.3) 77.3 (20.1)
Waist, cm 87.3 (21.8) 92.8 (15.8) 92.4 (18.1)
Hips, cm 99.7 (21.8) 105.8 (14.7) 105.0 (16.2)
Body mass index (BMI), kg/m2 28.5 (7.6) 28.4 (7.6) 28.5 (7.7)
Waist-to-hip ratio 0.88 (0.1) 0.88 (0.1) 0.88 (0.1)
Percentage body fat, % 32.7 (9.9) 33.2 (11.2) 33.6 (10.5)
Fat mass index, kg/m2 9.8 (5.5) 9.9 (6.0) 10.2 (6.0)
BMI at 18 years 20.1 (4.3) 19.8 (3.4) 20.3 (4.1)
Change in BMI from 18 years 5.0 (6.5) 7.7 (6.2) 5.5 (6.1)
aWaist-to-hip ratio > 0.85 for women; bwaist circumference ≥ 88 cm for women; cphysical activity levels: inactive was classiﬁed as not meeting guidelines, and
moderately active and active were classiﬁed as meeting guidelines of 150 minutes per week of moderate-to-vigorous physical activity. ∗Signiﬁcant diﬀerence
from no arthritis (P < 0 05) as determined by Kruskal-Wallis test; $signiﬁcant diﬀerence from osteoarthritis (P < 0 05) as determined by Student’s t-test.
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associated with excess body weight. Waist circumference,
waist-to-hip ratio, and percent body fat/fat mass are also
commonly associated with the metabolic complications of
obesity [24–26]. Some studies have attempted to include
more than one variable [27–30]; however, there is a lack of
research directly comparing these distinct measures of
adiposity in individuals with diﬀerent types of arthritis. The
results of the current study show a strong association
between diﬀerent measures of adiposity such as BMI, percent
body fat, FMI, and a change in BMI from 18 years of age in
participants without arthritis and those with rheumatoid
arthritis or osteoarthritis. BMI at 18 years of age has been
shown to be a strong predictor of obesity in adulthood,
and gain in BMI has been associated with increased risk
of disease (e.g., diabetes and hypertension, osteoarthritis, and
rheumatoid arthritis) [31–33].
Similar to our results, a signiﬁcant association has been
reported between BMI and percent fat mass, as well as the
correlation between percent fat mass and waist-to-hip ratio
[28]. Likewise, percent body fat and FMI were reported to
be signiﬁcantly higher in patients with rheumatoid arthritis
compared to controls [34]. Previous research suggests that
BMI and percent body fat are associated with osteoarthritis
of the hand, knee, and hip in both sexes [28–30]. In addition,
an association with the waist-to-hip ratio in patients with
hand osteoarthritis has been documented [28]. We did not
observe a signiﬁcant association in waist-to-hip ratio and
other adiposity measures in participants with either form
of arthritis or without arthritis; however, we were not able
to diﬀerentiate between the location of arthritis in the
current study. Adiposity measurements in relationship to
speciﬁc locations of arthritic joints may be considered in
future research.
The relationship linking arthritis and obesity is complex
and additional investigation is needed to better understand
the complex pathophysiology of the disease. Obesity is a
state of chronic low-grade inﬂammation and it is possible
that the deterioration and loss of cartilage in arthritis may
be due to an imbalance between proinﬂammatory and
anti-inﬂammatory cytokines that result in catabolic eﬀects
on cartilage [9–11, 35]. Recent reports suggest that factors
secreted directly from the adipose tissue, adipokines, may
be involved in the inﬂammatory process, as well as carti-
lage and bone remodeling [8]. Thus, we examined the
relationship between systemic markers (such as adipokines)
and arthritis in obese individuals with speciﬁc types
of arthritis.
Previous research into the molecular causes of rheuma-
toid arthritis has shown mixed results with some studies
reporting no diﬀerence or increased levels of adiponectin in
Table 2: Correlation between adiposity measures in nested case-control participants with and without arthritis in the Atlantic PATH cohort.
Waist
circumference
Body mass index
(BMI)
Waist-to-hip
ratio
Percentage body
fat
Fat mass
index
Change in BMI from
18 years
No arthritis
Waist circumference — — — — — —
Body mass index (BMI) 0.185 — — — — —
Waist-to-hip ratio 0.244∗ −0.079 — — — —
Percentage body fat 0.164 0.755∗ −0.065 — — —
Fat mass index 0.160 0.930∗ −0.057 0.903∗ — —
Change in BMI from
18 years
0.145 0.749∗ 0.003 0.323∗ 0.535∗ —
Rheumatoid arthritis
Waist circumference — — — — — —
Body mass index (BMI) −0.052 — — — — —
Waist-to-hip ratio 0.577∗ −0.224∗ — — — —
Percentage body fat −0.049 0.797∗ −0.250∗ — — —
Fat mass index −0.101 0.900∗ −0.293∗ 0.931∗ — —
Change in BMI from
18 years
−0.136 0.793∗ 0.080 0.268 0.481∗ —
Osteoarthritis
Waist circumference — — — — — —
Body mass index (BMI) 0.179 — — — — —
Waist-to-hip ratio 0.693∗ 0.061 — — — —
Percentage body fat 0.085 0.807∗ −0.011 — — —
Fat mass index 0.148 0.952∗ 0.037 0.935∗ — —
Change in BMI from
18 years
0.128 0.747∗ 0.087 0.365∗ 0.561∗ —
∗Signiﬁcance at P < 0 001.
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those with rheumatoid arthritis compared to those without
[36]. Although we observed slightly higher levels of both
adiponectin and leptin in participants with rheumatoid
arthritis, no signiﬁcant association was found. In contrast, a
meta-analysis of 6 prospective cohort studies showed that
leptin levels were higher in rheumatoid patients with higher
disease activity [37]. Interestingly, the duration of rheuma-
toid arthritis ranged from 14 months to 17 years and leptin
levels were highest in those with the shortest duration of
disease. Although we did not measure disease activity in the
current study, the average duration of rheumatoid arthritis
among participants was almost 16 years. Yoshino et al. exam-
ined the same 3 adipokines as the current study and reported
both higher levels of leptin and adiponectin in females with
rheumatoid arthritis but similar levels of resistin [38]. Impor-
tantly, the abovementioned study reported diﬀerences of
adipokines levels between sexes and was examining a popula-
tion with an average BMI within the normal range. These
distinctions between participants and studies may be impor-
tant when considering what types of adipokines may be
potential therapeutic targets in the future.
Much of the previous research in osteoarthritis suggested
higher circulating adipokine levels in osteoarthritis patients
[39–44], and although we observed higher adiponectin and
leptin levels in participants with osteoarthritis, only adipo-
nectin resulted in a signiﬁcant association with osteoarthritis.
It is worth noting that the extent of osteoarthritis may
inﬂuence adipokine levels as associations with adipokines
and grading or severity of disease have been documented
[12, 40, 42]. One study which examined adiponectin, leptin,
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Figure 1: Plasma (a) adiponectin, (b) leptin, and (c) resistin in participants without arthritis, with rheumatoid arthritis, andwith osteoarthritis.
Horizontal lines represent means± standard deviations, and dots, squares, and triangles represent individual data points from participants
without arthritis, with rheumatoid arthritis, and with osteoarthritis, respectively. Data are not statistically diﬀerent as determined by the
Kruskal-Wallis test.
Table 3: Logistic regression models of adipokines as predictor of
rheumatoid arthritis.
Odds ratio (95% CIs) P value
Adiponectin
Unadjusted 1.059 (0.990–1.133) 0.096
Model 1 1.059 (0.989–1.135) 0.100
Model 2 1.048 (0.977–1.125) 0.188
Leptin
Unadjusted 1.020 (0.994–1.047) 0.128
Model 1 1.016 (0.990–1.042) 0.222
Model 2 1.015 (0.989–1.041) 0.252
Resistin
Unadjusted 1.041 (0.994–1.090) 0.092
Model 1 1.038 (0.990–1.087) 0.123
Model 2 1.042 (0.991–1.096) 0.109
Model 1: adjusted for age; model 2: adjusted for age, education, smoking,
alcohol use, and fruit and vegetable intake.
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and resistin found that all 3 adipokines were elevated in those
with osteoarthritis; however, these patients all had severe
osteoarthritis and were signiﬁcantly older than control
participants [42]. In addition, the location of osteoarthritis
may also be worth considering when reporting inﬂammatory
mediators. For example, higher IL6 were reported in both the
synovial ﬂuid and serum of patients with hip osteoarthritis,
whereas serum leptin levels have been reported to be higher
in patients with knee osteoarthritis [45]. A limitation of the
current study is that no data on the location site of arthritis
was collected. Perhaps diﬀerent cytokines and adipokines
are distinct at various locations and stages of the disease
process. Furthermore, adipokines may be more predictive as
markers when combined with other established biomarkers
of osteoarthritis or inﬂammatory mediators involved in carti-
lage degradation. For instance, adiponectin levels have been
shown to correlate with inﬂammatory mediators as well as
enhance the secretion of inﬂammatory mediators from
cultured cartilage [12, 46].
A strength of the current study is that multiple measures
of obesity including BMI, waist circumference, waist-to-hip
ratio, and body composition were utilized to assess adiposity.
In addition, blood samples and objectively measured anthro-
pometric variables on the majority of participants in the
Atlantic PATH cohort are also major strengths. As with
any self-reported data, there are disadvantages, including
issues related to participant recall of disease and other health
and lifestyle factors. The Atlantic PATH data was limited to
the self-report of the disease history, age of diagnosis, type
of arthritis, and there was no site-speciﬁc information
provided. Site-speciﬁc arthritis may be considered for future
studies as a high BMI has been associated with an increased
odds ratio of osteoarthritis of the knee and hand but not
the hip [47]. As well, pharmacological management of
arthritis was not taken into account prior to examining the
nested case-control sample. Accordingly, future research
should explore the use of medications that may inﬂuence
plasma adipokines levels in these populations. Furthermore,
previous research has demonstrated that measurement of
cytokine levels in individuals with rheumatoid arthritis may
be augmented by interfering factors such as rheumatoid fac-
tor [48, 49]; however, similar to previous cytokine research,
not all adipokines may be inﬂuenced by such factors [50].
Rheumatoid factor was not measured in the current study,
but further investigation into the potential interference of
rheumatoid factor and other heterophilic antibodies with
multiplex immunoassays should be considered for future
work in this area.
5. Conclusions
In summary, the current nested case-control study examined
the levels of adipokines in female participants with arthritis
and obesity from a region of Canada that has particularly
high levels of the two diseases. The ﬁndings demonstrated a
signiﬁcant correlation between various types of adiposity
measures in participants with rheumatoid and osteoarthritis.
Adipokines adiponectin, leptin, and resistin were analyzed in
all groups; however, the only association was observed with
adiponectin and those with osteoarthritis. Future research
should focus on the complex relationship between adipo-
kines and arthritis in obese individuals with speciﬁc types
of arthritis, precisely how these levels change over time with
disease progression. The Atlantic PATH cohort is intended
to be longitudinal and data on participants will be collected
for up to 30 years, opening the door for further exploration
into the complex relationship between obesity and arthritis.
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